Možnosti liečby chronickej myeloidnej leukémie

    Fulltext (.pdf)

     

    Autori: Simona Liová, Miriam Tupá

    In: Zdravotnícke štúdie

    ISSN: 1337-723X

    Ročník: 14

    Číslo: 1

    Strany: 53-60

    Rok vydania: 2022

    Vydavateľ: VERBUM – vydavateľstvo Katolíckej univerzity v Ružomberku

    Abstract: Chronic myeloid leukemia is a hematopoietic malignancy resulting from the transformation of a primitive hematopoietic cell. It is a clonal myeloproliferative disease characterized by the presence of the Philadelphia chromosome, which results from a reciprocal translocation between chromosomes 9 and 22. CML is generally thought to develop from the transformation of primitive hematopoietic stem cells with the BCR-ABL fusion gene. The presence of a unique genetic abnormality with strong pathogenetic potential has enabled the development of specific pathological tyrosine kinase inhibitors. Their introduction into clinical practice, especially their effectiveness, have revolutionized the treatment management and prognosis of this disease, as evidenced by the median survival of patients diagnosed in the chronic phase.

    Keywords:  Chronic myeloid leukemia. BCR-ABL. Treatment. Tyrosine kinase inhibitors.

    Citácia:

    LIOVÁ, Simona, TUPÁ, Miriam . Možnosti liečby chronickej myeloidnej leukémie. In: Zdravotnícke štúdie [online]. Ružomberok: VERBUM – vydavateľstvo Katolíckej univerzity v Ružomberku, 2022, 14 (1), s. 53-60. ISSN 1337-723X. Dostupné na internete: